These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 18057521)

  • 1. The continuum of serous tumors of low malignant potential and low-grade serous carcinomas of the ovary.
    Wong KK; Gershenson D
    Dis Markers; 2007; 23(5-6):377-87. PubMed ID: 18057521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.
    Bonome T; Lee JY; Park DC; Radonovich M; Pise-Masison C; Brady J; Gardner GJ; Hao K; Wong WH; Barrett JC; Lu KH; Sood AK; Gershenson DM; Mok SC; Birrer MJ
    Cancer Res; 2005 Nov; 65(22):10602-12. PubMed ID: 16288054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphatic vascular invasion in ovarian serous tumors of low malignant potential with stromal microinvasion: a case control study.
    Sangoi AR; McKenney JK; Dadras SS; Longacre TA
    Am J Surg Pathol; 2008 Feb; 32(2):261-8. PubMed ID: 18223329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion.
    McKenney JK; Balzer BL; Longacre TA
    Am J Surg Pathol; 2006 Oct; 30(10):1209-21. PubMed ID: 17001150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of BRAF V600E mutant protein in epithelial ovarian tumors.
    Preusser M; Capper D; Berghoff AS; Horvat R; Wrba F; Schindl M; Schoppmann SF; von Deimling A; Birner P
    Appl Immunohistochem Mol Morphol; 2013 Mar; 21(2):159-64. PubMed ID: 22820660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas.
    Tung CS; Mok SC; Tsang YT; Zu Z; Song H; Liu J; Deavers MT; Malpica A; Wolf JK; Lu KH; Gershenson DM; Wong KK
    Mod Pathol; 2009 Sep; 22(9):1243-50. PubMed ID: 19525924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
    Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
    Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis.
    Dehari R; Kurman RJ; Logani S; Shih IeM
    Am J Surg Pathol; 2007 Jul; 31(7):1007-12. PubMed ID: 17592266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The Fallopian tube odyssey: from the ovary to the tube. About high-grade serous ovarian carcinoma].
    Chêne G; Dauplat J; Radosevic-Robin N; Cayre A; Penault-Llorca F
    Bull Cancer; 2013; 100(7-8):757-64. PubMed ID: 23831931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-malignant potential epithelial tumors of the ovary: a clinicopathological study.
    Hassan E; Koumantaki Y; Stefanaki K; Matalliotakis I; Koumantakis E
    Eur J Gynaecol Oncol; 1998; 19(2):170-2. PubMed ID: 9611060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of p16INK4A expression in low-grade ovarian serous carcinomas.
    Schlosshauer PW; Deligdisch L; Penault-Llorca F; Fatemi D; Qiao R; Yao S; Pearl M; Yang Z; Sheng T; Dong J
    Int J Gynecol Pathol; 2011 Jan; 30(1):22-9. PubMed ID: 21131838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling.
    Gilks CB; Vanderhyden BC; Zhu S; van de Rijn M; Longacre TA
    Gynecol Oncol; 2005 Mar; 96(3):684-94. PubMed ID: 15721412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance.
    Salani R; Kurman RJ; Giuntoli R; Gardner G; Bristow R; Wang TL; Shih IM
    Int J Gynecol Cancer; 2008; 18(3):487-91. PubMed ID: 17692090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic alterations in epithelial ovarian tumors analyzed by comparative genomic hybridization.
    Hauptmann S; Denkert C; Koch I; Petersen S; Schlüns K; Reles A; Dietel M; Petersen I
    Hum Pathol; 2002 Jun; 33(6):632-41. PubMed ID: 12152163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-grade serous ovarian cancer: a unique disease.
    Schmeler KM; Gershenson DM
    Curr Oncol Rep; 2008 Nov; 10(6):519-23. PubMed ID: 18928667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noninvasive and invasive micropapillary (low-grade) serous carcinoma of the ovary: a clinicopathologic analysis of 135 cases.
    Smith Sehdev AE; Sehdev PS; Kurman RJ
    Am J Surg Pathol; 2003 Jun; 27(6):725-36. PubMed ID: 12766576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up.
    Longacre TA; McKenney JK; Tazelaar HD; Kempson RL; Hendrickson MR
    Am J Surg Pathol; 2005 Jun; 29(6):707-23. PubMed ID: 15897738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastasis-associated genes profile in ovarian serous papillary carcinomas.
    Farghaly SA
    Am J Obstet Gynecol; 2007 Nov; 197(5):555; author reply 555-6. PubMed ID: 17980211
    [No Abstract]   [Full Text] [Related]  

  • 19. Expression of selected epithelial-mesenchymal transition transcription factors in serous borderline ovarian tumors and type I ovarian cancers.
    Sadlecki P; Jóźwicki J; Antosik P; Grabiec M
    Tumour Biol; 2018 Jun; 40(6):1010428318784807. PubMed ID: 29952249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serous tumors of the ovary (borderline tumors and carcinomas) with and without micropapillary features.
    Prat J
    Int J Gynecol Pathol; 2003 Jan; 22(1):25-8. PubMed ID: 12496694
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.